Assessing tuberculosis risk in Crohn's disease patients receiving biologic therapies: real-world insights from Japan.
作者信息
Lee Jung Won, Han Yoo Min
机构信息
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Department of Internal Medicine and Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea.
出版信息
Intest Res. 2025 Jul;23(3):231-232. doi: 10.5217/ir.2025.00117. Epub 2025 Jul 29.
Abstract
摘要
相似文献
1
Assessing tuberculosis risk in Crohn's disease patients receiving biologic therapies: real-world insights from Japan.评估接受生物疗法的克罗恩病患者的结核病风险：来自日本的真实世界见解。
Intest Res. 2025 Jul;23(3):231-232. doi: 10.5217/ir.2025.00117. Epub 2025 Jul 29.
2
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.比较生物疗法治疗中重度克罗恩病的疗效和安全性：系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014. doi: 10.1016/S2468-1253(21)00312-5. Epub 2021 Oct 22.
3
Epidemiology and Steroid Dependency Reduction in Crohn's Disease During the Biologics Era: A Nationwide Population-Based Study.生物制剂时代克罗恩病的流行病学及类固醇依赖减少：一项基于全国人口的研究
Adv Ther. 2025 Jun 23. doi: 10.1007/s12325-025-03245-0.
4
Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.在克罗恩病生物初治与生物经验患者中乌司奴单抗的临床、内镜和放射学疗效：来自加拿大一大型中心的真实世界经验。
Inflamm Bowel Dis. 2023 Jun 1;29(6):866-874. doi: 10.1093/ibd/izac149.
5
Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.比较生物疗法在诱导瘘管性克罗恩病缓解和应答中的疗效：系统评价和随机对照试验的网络荟萃分析。
Inflamm Bowel Dis. 2023 Mar 1;29(3):367-375. doi: 10.1093/ibd/izac103.
6
Which first? Surgery or biologic therapy for ileocolic Crohn's disease in the real world.在现实世界中，回结肠型克罗恩病应先进行手术还是生物治疗？
Expert Rev Gastroenterol Hepatol. 2025 Jul;19(7):817-824. doi: 10.1080/17474124.2025.2519167. Epub 2025 Jun 12.
7
Real-world outcomes from the UK IBD Registry on second-line biologic therapy following anti-TNF exposure in Crohn's disease: results from the BISCUITS study.英国炎症性肠病注册中心关于克罗恩病抗TNF治疗后二线生物治疗的真实世界结果：BISCUITS研究结果
Therap Adv Gastroenterol. 2025 Jul 28;18:17562848251352446. doi: 10.1177/17562848251352446. eCollection 2025.
8
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.对病情缓解的克罗恩病患者停用免疫抑制剂或生物疗法。
Cochrane Database Syst Rev. 2018 May 12;5(5):CD012540. doi: 10.1002/14651858.CD012540.pub2.
9
Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.炎症性肠病的治疗序贯策略：利用真实世界证据确定vedolizumab 在长期克罗恩病控制中的最佳位置。
United European Gastroenterol J. 2024 Jun;12(5):574-584. doi: 10.1002/ueg2.12563. Epub 2024 May 8.
10
Treatment Patterns in Newly Diagnosed Patients with Crohn's Disease Who Received Biologics Following Diagnosis: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Medical Claims Database in Japan.在诊断后接受生物制剂治疗的新诊断克罗恩病患者的治疗模式：一项使用日本医疗索赔数据库的全国性、回顾性、纵向、观察性研究。
Digestion. 2023;104(2):109-120. doi: 10.1159/000527045. Epub 2022 Nov 30.
本文引用的文献
1
Tuberculosis risk in patients with Crohn's disease on biologics: a retrospective analysis of the Japanese Medical Claims Database.接受生物制剂治疗的克罗恩病患者的结核病风险：日本医疗理赔数据库的回顾性分析
Intest Res. 2025 Jul;23(3):309-317. doi: 10.5217/ir.2024.00076. Epub 2024 Aug 19.
2
Precision medicine in inflammatory bowel diseases.炎症性肠病中的精准医学
Intest Res. 2024 Jan;22(1):8-14. doi: 10.5217/ir.2023.00087. Epub 2023 Nov 9.
3
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.亚洲炎症性肠病患者的感染并发症：第八届亚洲克罗恩病和结肠炎组织会议上一项基于网络的多国调查结果
Intest Res. 2023 Jul;21(3):353-362. doi: 10.5217/ir.2023.00013. Epub 2023 Jul 27.
4
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.综述文章：接受免疫抑制治疗的炎症性肠病患者中的潜伏性结核——风险、筛查、诊断和管理。
Aliment Pharmacol Ther. 2022 Jul;56(1):6-27. doi: 10.1111/apt.16952. Epub 2022 May 20.
5
Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease.结核菌素皮肤试验与干扰素-γ释放试验在炎症性肠病潜伏性结核筛查中的一致性
Intest Res. 2020 Jul;18(3):306-314. doi: 10.5217/ir.2019.00116. Epub 2020 Mar 20.
6
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy.接受抗肿瘤坏死因子治疗的炎症性肠病患者中结核病的临床特征及转归
Korean J Gastroenterol. 2020 Jan 25;75(1):29-38. doi: 10.4166/kjg.2020.75.1.29.
7
A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.一项前瞻性研究，旨在监测接受抗肿瘤坏死因子治疗的炎症性肠病和免疫介导的炎症性疾病患者的结核病。
J Crohns Colitis. 2018 Jul 30;12(8):954-962. doi: 10.1093/ecco-jcc/jjy057.
8
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.生物疗法与炎症性肠病患者感染和恶性肿瘤风险：系统评价和网络荟萃分析。
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14.
9
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis.炎症性肠病患者的机会性感染：预防与诊断
Gut. 2008 Apr;57(4):549-58. doi: 10.1136/gut.2006.114660. Epub 2008 Jan 4.
Zotero 插件